Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel S Peiffer

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2026
What is Optimal Neoadjuvant Therapy in HER2-Positive Breast Cancer?Daniel S Peiffer, Caitlin Maloney, Nan Chen
Expert Opinion on Investigational Drugs|February 7, 2026
Triple negative breast cancer: what clinical progress have we seen in the last 5 years?Daniel S Peiffer, Maeve A Hennessy, Rita Nanda
NPJ Breast Cancer|September 1, 2020
DAXX-inducing phytoestrogens inhibit ER+ tumor initiating cells and delay tumor developmentDaniel S Peiffer, Emily Ma, Debra Wyatt, et al.
Cancer Immunology, Immunotherapy : CII|February 24, 2017
FOXO3, estrogen receptor alpha, and androgen receptor impact tumor growth rate and infiltration of dendritic cell subsets differentially between male and female miceMatthew G Thompson, Daniel S Peiffer, Michelle Larson, et al.
Journal of Berry Research|July 7, 2018
Inhibition of the development of N-nitrosomethylbenzylamine-induced esophageal tumors in rats by strawberries and aspirin, alone and in combinationPan Pan, Daniel S Peiffer, Yi-Wen Huang, et al.
The Journal of Steroid Biochemistry and Molecular Biology|March 1, 2019
Estrogen-mediated protection against coronary heart disease: The role of the Notch pathwayFrancesca Fortini, Francesco Vieceli Dalla Sega, Cristiana Caliceti, et al.
Cancer Research|August 8, 2019
DAXX Suppresses Tumor-Initiating Cells in Estrogen Receptor-Positive Breast Cancer Following Endocrine TherapyDaniel S Peiffer, Debra Wyatt, Andrei Zlobin, et al.
JAMA Oncology|February 23, 2023
Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer DatabaseDaniel S Peiffer, Fangyuan Zhao, Nan Chen, et al.
The Journal of Investigative Dermatology|January 31, 2015
CCL22 to Activate Treg Migration and Suppress Depigmentation in VitiligoJonathan M Eby, Hee-Kap Kang, Sean T Tully, et al.
JAMA Network Open|February 3, 2026
Adjuvant Chemotherapy Use for Hormone Receptor-Positive, ERBB2-Negative Breast Cancer After RxPONDER TrialJincong Q Freeman, Poornima Saha, Daniel S Peiffer, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2026
What is Optimal Neoadjuvant Therapy in HER2-Positive Breast Cancer?Daniel S Peiffer, Caitlin Maloney, Nan Chen
Expert Opinion on Investigational Drugs|February 7, 2026
Triple negative breast cancer: what clinical progress have we seen in the last 5 years?Daniel S Peiffer, Maeve A Hennessy, Rita Nanda
NPJ Breast Cancer|September 1, 2020
DAXX-inducing phytoestrogens inhibit ER+ tumor initiating cells and delay tumor developmentDaniel S Peiffer, Emily Ma, Debra Wyatt, et al.
Cancer Immunology, Immunotherapy : CII|February 24, 2017
FOXO3, estrogen receptor alpha, and androgen receptor impact tumor growth rate and infiltration of dendritic cell subsets differentially between male and female miceMatthew G Thompson, Daniel S Peiffer, Michelle Larson, et al.
Journal of Berry Research|July 7, 2018
Inhibition of the development of N-nitrosomethylbenzylamine-induced esophageal tumors in rats by strawberries and aspirin, alone and in combinationPan Pan, Daniel S Peiffer, Yi-Wen Huang, et al.
The Journal of Steroid Biochemistry and Molecular Biology|March 1, 2019
Estrogen-mediated protection against coronary heart disease: The role of the Notch pathwayFrancesca Fortini, Francesco Vieceli Dalla Sega, Cristiana Caliceti, et al.
Cancer Research|August 8, 2019
DAXX Suppresses Tumor-Initiating Cells in Estrogen Receptor-Positive Breast Cancer Following Endocrine TherapyDaniel S Peiffer, Debra Wyatt, Andrei Zlobin, et al.
JAMA Oncology|February 23, 2023
Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer DatabaseDaniel S Peiffer, Fangyuan Zhao, Nan Chen, et al.
The Journal of Investigative Dermatology|January 31, 2015
CCL22 to Activate Treg Migration and Suppress Depigmentation in VitiligoJonathan M Eby, Hee-Kap Kang, Sean T Tully, et al.
JAMA Network Open|February 3, 2026
Adjuvant Chemotherapy Use for Hormone Receptor-Positive, ERBB2-Negative Breast Cancer After RxPONDER TrialJincong Q Freeman, Poornima Saha, Daniel S Peiffer, et al.
Pageof 2